Phosphomannomutase deficiency (PMM2-CDG): Ataxia and cerebellar assessment by García-Cazorla, Angels et al.
Serrano et al. Orphanet Journal of Rare Diseases  (2015) 10:138 
DOI 10.1186/s13023-015-0358-yRESEARCH Open AccessPhosphomannomutase deficiency (PMM2-
CDG): ataxia and cerebellar assessment
Mercedes Serrano1*, Víctor de Diego1, Jordi Muchart2, Daniel Cuadras4, Ana Felipe5, Alfons Macaya5,
Ramón Velázquez6, M. Pilar Poo1, Carmen Fons1, M. Mar O’Callaghan1, Angels García-Cazorla1, Cristina Boix1,
Bernabé Robles7, Francisco Carratalá8, Marisa Girós9, Paz Briones9, Laura Gort9, Rafael Artuch3, Celia Pérez-Cerdá10,
Jaak Jaeken11, Belén Pérez10 and Belén Pérez-Dueñas1Abstract
Background: Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of
glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is
observed, and cerebellar dysfunction is their main daily functional limitation. Different therapeutic agents are under
development, and clinical evaluation of drug candidates will require a standardized score of cerebellar dysfunction.
We aim to assess the validity of the International Cooperative Ataxia Rating Scale (ICARS) in children and
adolescents with genetically confirmed PMM2-CDG deficiency. We compare ICARS results with the Nijmegen
Pediatric CDG Rating Scale (NPCRS), neuroimaging, intelligence quotient (IQ) and molecular data.
Methods: Our observational study included 13 PMM2-CDG patients and 21 control subjects. Ethical permissions
and informed consents were obtained. Three independent child neurologists rated PMM2-CDG patients and control
subjects using the ICARS. A single clinician administered the NPCRS. All patients underwent brain MRI, and the
relative diameter of the midsagittal vermis was measured. Psychometric evaluations were available in six patients.
The Mann–Whitney U test was used to compare ICARS between patients and controls. To evaluate inter-observer
agreement in patients’ ICARS ratings, intraclass correlation coefficients (ICC) were calculated. ICARS internal consistency
was evaluated using Cronbach’s alpha. Spearman’s rank correlation coefficient test was used to correlate ICARS with
NPCRS, midsagittal vermis relative diameter and IQ.
Results: ICARS and ICARS subscores differed between patients and controls (p < 0.001). Interobserver agreement of
ICARS was “almost perfect” (ICC = 0.99), with a “good” internal reliability (Cronbach’s alpha = 0.72). ICARS was
significantly correlated with the total NPCRS score (rs 0.90, p < 0.001). However, there was no agreement regarding
categories of severity. Regarding neuroimaging, inverse correlations between ICARS and midsagittal vermis relative
diameter (rs −0.85, p = 0.003) and IQ (rs −0.94, p = 0.005) were found. Patients bearing p.E93A, p.C241S or p.R162W
mutations presented a milder phenotype.
Conclusions: ICARS is a reliable instrument for assessment of PMM2-CDG patients, without significant inter-rater
variability. Despite our limited sample size, the results show a good correlation between functional cerebellar
assessment, IQ and neuroimagingFor the first a correlation between ICARS, neuroimaging and IQ in PMM2-CDG
patients has been demonstrated.
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Congenital disorders of glycosylation (CDG) comprise
some 100 genetic disorders caused by impaired synthesis
of glycoconjugates [1, 2]. Mammals have eight major
glycosylation pathways in the endoplasmic reticulum and
Golgi, and the N-linked glycosylation pathway is by far the
best studied [3, 4].
Phosphomannomutase deficiency (PMM2-CDG, previ-
ously CDG-Ia), is the most frequent congenital disorder of
N-linked glycosylation and accounts for approximately
80 % of all diagnosed patients since it was described in
1980 [5]. PMM2-CDG is caused by mutations in PMM2
(*#601785OMIM), encoding an enzyme that catalyzes the
second step in the N-glycosylation pathway, the conver-
sion of mannose-6-phosphate to mannose-1-phosphate.
The CNS and peripheral nervous system are prime tar-
gets of PMM2-CDG deficiency, but many other systems
are affected, as in other CDG [2].
Early clinical signs of PMM2-CDG are usually abnormal
fat distribution, inverted nipples, strabismus and hypotonia.
Infants develop ataxia, psychomotor delay and extraneuro-
logical manifestations, including failure to thrive, enterop-
athy, hepatic dysfunction, coagulation abnormalities and
cardiac and renal involvement. The phenotype is extremely
variable: some patients develop a severe systemic illness
leading to early death [6, 7], and some patients show
milder forms with variable systemic and mild neuro-
logical involvement [2, 8].
Cerebellar involvement is a common feature of PMM2-
CDG. At birth, most children have marked hypotrophy of
the vermis and cerebellar hemispheres, followed by pro-
gression towards atrophy [9, 10]. However, in mild cases,
brain MRI may be normal [8]. Many key neurological
symptoms found in PMM2-CDG patients can be ex-
plained by this cerebellar syndrome (ataxia, dysmetria,
tremor, abnormal eye movements, dysarthria, and cogni-
tive deficits or low intelligence quotient (IQ)), leading to
major disability.
The recently validated Nijmegen Pediatric CDG
Rating Scale (NPCRS) based on the Newcastle Paediatric
Mitochondrial Disease Scale, evaluates multisystemic
data, including neurological involvement [11]. How-
ever, this scale does not specifically assess cerebellar
symptoms.
The International Cooperative Ataxia Rating Scale
(ICARS) is a neurologist-completed scale developed to
assess cerebellar ataxia [12], that has been recently vali-
dated in healthy children above 4 years of age [13]. ICARS
has been used in some genetic diseases such as Friedreich
ataxia, coenzyme Q deficiency and others [14, 15]. How-
ever, no standardized tools have been used to evaluate
cerebellar dysfunction in PMM2-CDG patients.
In the present study, we aim to assess the validity of the
ICARS in children and adolescents with geneticallyconfirmed PMM2-CDG deficiency. ICARS results are
compared with NPCRS, neuroimaging, IQ and molecular
data.
Methods
Eligible patients included children and adolescents older
than four years of age with a molecular diagnosis of
PMM2-CDG. Exclusion criteria were severe cognitive
impairment or behavioral problems precluding complete
administration of the scales.
A pediatric age-matched control population was se-
lected. The control sample included children older than
four years recruited by open advertisement or from chil-
dren attending the Hospital Sant Joan de Déu (HSJD)
outpatient clinic for mild, untreated tensional headache.
Exclusion criteria were cognitive or behavioral problems.
ICARS involves a 100-point rating scale with higher
scores denoting more evident clinical abnormalities
(https://commondataelements.ninds.nih.gov/Doc/NOC/
International_Cooperative_Ataxia_Rating_Scale_NOC_
Link.pdf ) [12]. ICARS includes subscores for posture
and gait (0–34), kinetic functions (0–52), speech abnor-
malities (0–8) and oculomotor function (0–6). Three inde-
pendent child neurologists rated PMM2-CDG patients
simultaneously with the ICARS. All of the examinations
were videotaped following a standardized protocol for
educational and revision purposes. The NPCRS was ad-
ministered by one of the three child neurologists on the
same day as the ICARS assessment.
Brain MRI exams included T1 and T2-weighted,
diffusion-weighted and FLAIR sequences. An adapted
measurement procedure similar to the classic fetal cere-
bellum measurements was applied [16, 17]. The relative
diameter of the midsagittal vermis was calculated using a
midsagittal section and measuring total posterior cranial
fossa diameter in a linear segment from the posterior
commissura to the opisthium and the largest sagittal
diameter of the cerebellum parallel to the previous linear
segment. The ratio of the cerebellum diameter over the
total posterior cranial fossa diameter was used (Fig. 1).
Only those patients with MRI studies performed within
the two years preceding ICARS assessment were included
in this analysis (n = 9).
Biochemical and molecular studies were carried out in
all PMM2-CDG patients enrolled. Genetic analysis was
performed in the CEDEM-UAM in Madrid. Total mRNA
and genomic DNA were isolated from venous whole
blood or patient-derived fibroblasts using a MagnaPure
system following the manufacturer’s protocol (Roche
Applied Science, Indianapolis). Mutational analysis was
performed by genomic DNA analysis both in patients’ and
parents’ samples to assure that both changes are on differ-
ent alleles and to rule out the presence of a large genomic
rearrangement. In some cases the effect on splicing was
Fig. 1 Midsagittal vermis relative diameter (MVRD). Legend: Midsagittal
vermis relative diameter (MVRD) was calculated using a midsagittal
section and measuring total posterior cranial fossa diameter (a linear
segment from the posterior commissura to the occipital bone at the
foramen magnum) and the largest axial diameter of the cerebellum
parallel to the previous linear segment. The fraction (cerebellum
diameter/total posterior cranial fossa diameter) is used to express the
proportion of both values: MVRD ¼ 100 aA. The image represents MVRD
calculation of patient 5, with a MVRD result of 49 %
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cDNA and genomic DNA amplifications were designed
using the ENSEMBL database (http://www.ensembl.org/
index.html, ENSG00000140650) and GenBank accession
number NM_000303.2. Segregation genetic studies were
performed in all patients. Maternal isodisomy was de-
tected in patients 12 and 13 by SNP array analysis (Infi-
nium CytoSNP-850 K BeadChip).
For intelligence evaluation, six patients received struc-
tured neuropsychological testing; their global IQ, obtained
from WISC-IV-R or K-BIT tests, was used for analysis.
Ethical permission for the study was obtained from the
Research & Ethics Committee of the HSJD. Parents gave
their written informed consent and children/adolescents
gave their assent. Samples were obtained in accordance
with the Helsinki Declaration of 1964, as revised in
October 2013 in Fortaleza, Brazil.
Statistical analysis was performed using SPSS V.22.0
(Armonk, NY: IBM Corp.). The Mann–Whitney U test
was used to compare ICARS and ICARS subscales be-
tween patients and controls. To evaluate inter-observer
agreement in patients’ ICARS and ICARS sub-scales,
intraclass correlation coefficients (ICC) were calculated.
Internal consistency of the ICARS scale and its sub-
scales was evaluated using Cronbach’s alpha. Spearman’s
rank correlation coefficient test was used to study the
relationship between the ICARS and the NPCRS, mid-sagittal vermis relative diameter and IQ. To avoid the
confounding effect of age in the patient sample, a new
ICARS value for every patient was obtained subtracting
the mean values of the ICARS found in our control
population at different ages. All statistical tests were
two-sided. P-values <0.05 were considered significant.
Results
Thirteen PMM2-CDG children (mean age 9.3 years (SD
3.5; range [4.9-16.2]); five males, eight females) were
included in the study. One teenager affected by PMM2-
CDG was excluded due to severe cognitive impairment
that precluded the assessment of ICARS. Tables 1 and 2
show clinical, radiological and molecular data, ICARS
and NPCRS results. Twenty-one children between the
ages of four and fifteen years were included in the study
as control subjects (mean age 8.41 years (SD 3.2; Range
[4.0-14.3]); 13 males, eight females). Eleven were recruited
by open advertisement, and ten were outpatients.
ICARS and ICARS subscores were significantly different
between patients and controls (patients’ mean 41.1 vs.
controls’ mean 1.3; p = 0.01) (Fig. 2a). There was a statisti-
cally significant inverse correlation between the controls’
age and ICARS that was not present in patients (rs −0.86,
p < 0.001).
The ICCs for interobserver agreement of ICARS (three
different observers) was scored “almost perfect” (ICC =
0.99), with an internal reliability when the four subscales
are included scoring as “good” (Cronbach’s alpha = 0.72).
Only exclusion of the oculomotor subscore would have
increased Cronbach’s alpha. Inter-item evaluation in every
subscale reliability was scored “excellent” for postural/gait,
kinetic and dysarthria subscores (0.96, 0.94 and 0.88, re-
spectively) and “poor” for the oculomotor subscale (0.20).
The ICARS score was positively correlated with the
total NPCRS score (rs 0.90, p < 0.001) (Fig. 2b). However,
patients with high ICARS values (60, 61 and 70, respect-
ively) were in the low-moderate category of severity
according to the NPCRS, and only the most severe
patient (79 total ICARS) was in the low range of the
severe category in the NPCRS (Fig. 2b). Regarding
the NPCRS sections, ICARS correlated with Section
I (Current Function) (rs 0.92, p < 0.001), and Section
III (Current Clinical Assessment) (rs 0.88, p < 0.001) but
not with section II (System Specific Involvement) (rs 0.35,
p = 0.27).
Regarding the genetic basis, 14 different previously de-
scribed mutations were identified, and one novel mutation
(c.523 + 3A >G). Eleven patients were compound hetero-
zygous and two were homozygous for the p.P113L or
p.E139K. Both patients presented a maternal isodisomy.
Transcriptional profile analysis of patient 6 patient-derived
fibroblasts revealed an aberrant transcript due to skipping
from exon 3 to 6 (r.179_523del345, p.Val60_Ile174del).
Table 1 Molecular findings and multiorgan characteristics
Patient/Sex 1 Male 2 Female 3 Female 4 Male 5 Male 6 Female 7 Female 8 Male 9 Female 10 Female 11 Female 12 Female 13 Male
Molecular
findings
p.E93A/
p.R141H
p.R123Q/
p.C241S
p.F157S/
p.C241S
p.L32R/
p.R141H
p.R162W/
c.523 +
3A > G
p.F157S/
p.R162W
p.P113L/
p.D209G
p.C241S/
p.R141H
p.T237M/
c.640-9
T > G
p.P113L/
c.353C > T +
c.550C > A
p.R123X/
p.I153T
p.P113L/
p.P113L
p.E139K/
p.E139K
Age at
evaluation/
age at onset
15 years/
21 months
6 years/
9 months
8 years/
8 months
7 years/
Newborn
10 years/
3 months
10 years/
8 months
11 years/
Newborn
5 years/
2.5 years
11 years/
8 months
8 years/
7 months
16 years/
Newborn
6 years/
3 months
11 years/
Newborn
Dysmorphic
features
Large normal
setting ears
Almond
slanted
eyes
No Anteverted
ears
Inverted
nipples
Lipodystrophy Almond
slanted eyes,
lipodystrophy
No Almond
slanted
eyes
Almond
slanted
eyes, low
anteverted
ears,
lipodystrophy
Almond
slanted eyes,
thick lips,
pronounced
cheekbones,
lipodystrophy
Almond
slanted
eyes,
broad face,
large
mouth,
lipodystrophy,
Almond
slanted eyes,
broad face,
large mouth,
lipodystrophy
Cardiac
involvement
No No No No No No No No No No No PDA Truncus
arteriosus
Digestive
involvement
Diarrhea,
hypoglycemia
No No Vomits No ↑ALT ↑ALT, AST
(only perinatal
period)
No ↑ALT, AST Growth failure,
hypoglycemia
Vomits,
growth
failure,
diarrhea
↑ALT, AST Failure to
drive
Coagulation ↓ AT-III, PC ↓ AT-III,
PC, PS
↓ AT-III, PC ↓ AT-III, PC Normal ↑ PT; ↓AT-III,
PS
↓ PC, PS No ↓FXI ↑PT, aPTT, ↓ aPTT ↓ AT-III ↑PT
↓AT-III, PC, PS
Endocrine
involvement
No No No No No No Hypergonadotropic
hypogonadism
No No Mild ↑TSH,
hypoglycemia
Delayed
puberty
ND No
Kidney
involvement
Nephro
calcinosis
No No No No No No No No ↑Echogenicity,
nephrolithiasis
Proteinuria No No
Eye
abnormalities
Strabismus,
pigmentary
retinopathy
Strabismus
upgaze
deviation
Strabismus Strabismus,
hypermetropia,
astigmatism
Strabismus,
saccadic
movements
hypermetropia
Strabismus,
hypermetropia
Strabismus,
hypermetropia,
astigmatism,
abnormal ERG
No Strabismus Strabismus,
upgaze
deviation,
saccadic
movements
Strabismus,
upgaze
deviation,
retinopathy,
hypermetropia
Strabismus,
hypermetropia
Strabismus
PDA Persistent ductus arteriosus, ALT Alanine transaminase, AST Aspartate transaminase, ↑ Increased values, ↓ Decreased values, AT-III Antithrombin III, PC Protein C, PS Protein S, FXI Coagulation factor XI,
aPTT Activated partial thromboplastin time, FIX Coagulation factor IX, PT Prothrombin time, ND No data available, TSH Thyroid stimulating hormone
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Table 2 Molecular findings and neurological evaluation (neuroimaging, IQ, NPCRS and ICARS results)
Patient/Sex 1 Male 2 Female 3 Female 4 Male 5 Male 6 Female 7 Female 8 Male 9 Female 10 Female 11 Female 12 Female 13 Male
Molecular
findings
p.E93A/
p.R141H
p.R123Q/
p.C241S
p.F157S/
p.C241S
p.L32R/
p.R141H
p.R162W/
c.523 + 3A > G
p.F157S/
p.R162W
p.P113L/
p.D209G
p.C241S/
p.R141H
p.T237M/
c.640-9 T > G
p.P113L/
c.353C > T +
c.550C > A
p.R123X/
p.I153T
p.P113L/
p.P113L
p.E139K/p.E139K
Age at
evaluation
15 years 6 years 8 years 7 years 10 years 10 years 11 years 5 years 11 years 8 years 16 years 6 years 11 years
Peripheral
neuropathy
Motor-
sensory
axonal n
europathy
No NC/
↓DTR
No NC/
↓DTR
No No NC/↓DTR Slow nerve
conduction
No No NC/
↓DTR
No NC/
↓DTR
Slow nerve
conduction
velocity
Slow nerve
conduction
velocity
No NC/↓DTR No NC/↓DTR
Epilepsy No No No No No No No No No No No No Yes
Psychometric
evaluation
IQ 91
(WISC-IV)
ND IQ 89
(WISC-IV)
ND IQ 78 (K-BIT) IQ 59
(WISC-IV)
ND ND ND IQ 66 (K-BIT) IQ 40 (K-BIT) ND ND
MRI findings Mild
prominence
cerebellar
folia
Cerebellar
vermis
atrophy
Global
cerebellar
atrophy
ND Global
cerebellar
atrophy
Global
cerebellar
atrophy
Global
cerebellar
atrophy
Global
cerebellar
atrophy
Cerebellar
vermis
atrophy
Global
cerebellar
atrophy,
juxtacortical
signal change
Global
cerebellar
atrophy with
pons atrophy
Global
cerebellar
atrophy
Global cerebellar
and pons atrophy,
ventricular
enlargement
MRI MVRD 67 % 46 % No recent
MRIa
No recent
MRIa
49 % 46 % 35 % No recent
MRIa
No recent
MRIa
35 % 29 % 36 % 28 %
NPCRS 6 8 8 12 8 11 20 13 16 18 22 16 27
ICARS 4 10 17 18 23 34 47 50 60 61 62 70 79
NC Nerve conduction studies, DTR Deep tendon reflexes, IQ Intelligence quotient, WISC-IV Wechsler Intelligence Scale for Children, Fourth edition, K-BIT Kaufman Brief Intelligence Test, Second edition,
MVRD midsagittal vermis relative diameter, NPCRS Nijmegen Pediatric CDG Rating Score, ICARS International Cerebellar Assessment Rating Scale
aSee criteria in the text to include MRI in the analysis
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Fig. 2 ICARS results in patients versus control subjects, and correlations with NPCRS, neuroimaging and IQ findings. Legends: a ICARS: Patients’
mean 41.1 vs Controls’ mean 1.3 (p < 0.01); Postural-gait subscore: Patients’ mean 15.3 vs Controls’ mean 0.4 (p < 0.01); Kinetic subscore: Patients’
mean 20.2 vs Controls’ mean 0.8 (p < 0.01); Dysarthria subscore: Patients’ mean 3.5 vs Controls’ mean 0.1 (p < 0.01); Oculomotor subscore: Patients’
mean 1.7 vs Controls’ mean 0.1 (p < 0.01). b ICARS was statistically correlated with NPCRS with a positive coefficient of correlation (rs 0,90, p < 0.001).
Regarding NPCRS sections, ICARS was correlated with Section I (Current Function) (rs 0.92, p = 0.001), and Section III (Current Clinical Assessment)
(rs 0.88, p < 0.001) but not with Section II (System Specific Involvement) (rs 0.35, p = 0.27). c ICARS is negatively correlated with midsagittal vermis
relative diameter (rs −0.87, p = 0.003). d There is a negative correlation between ICARS and intelligence quotient (rs −0.94, p = 0.005)
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presented a milder phenotype with less severe ICARS
and milder cerebellar findings on MRI. Patients bear-
ing p.P113L and E139K presented the most severe
ICARS and cerebellar atrophy (Fig. 3).
All patients showed different degrees of cerebellar
atrophy on MRI, mostly vermian atrophy. The cerebellar
atrophy was more evident in those with higher ICARS
(Fig. 3). An inverse correlation between midsagittal vermis
relative diameter and ICARS was found (rs −0.85, p =0.003) (Fig. 2c). Midsagittal vermis relative diameter was
also inversely correlated with NPCRS (rs −0.95, p < 0.001).
Concerning IQ, despite the small number of patients
available, there was a negative correlation between ICARS
and IQ (rs −0.94, p = 0.005) (Fig. 2d), NPCRS and IQ
(rs −0.94, p = 0.005) and midsagittal vermis relative
diameter and IQ (rs −0.90, p = 0.037).
To avoid the confounding effect of age in the patients’
sample, a new ICARS value for every patient was ob-
tained subtracting the mean values of ICARS found in
Fig. 3 ICARS and neuroimaging findings
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described significant correlations between ICARS and
NPCRS, MRI findings or IQ remained unchanged when
the new ICARS value was introduced into the analyses.
Discussion
ICARS is a commonly used evaluation for patients with
ataxia. It is an exhaustive scale from which some other
derivatives, such as BARS (Brief Ataxia Rating Scale),
have been created to increase the speed of the evalu-
ation. The value of ICARS, BARS and SARA (Scale for
the Assessment and Rating of Ataxia) have recently been
validated in the pediatric population above 4 years of
age [13]. SARA includes a restricted number of items;
for instance, oculomotor abnormalities are not included,
which is a major drawback because they are frequently
found in PMM2-CDG patients. The previous evidence
of ICARS reliability when applied to children underlines
the necessity of age correction in the interpretation of
absolute ICARS results. This is particularly true in the
sub-scores of posture and gait and limb coordination, as
both areas are the most influenced by variation in fine
and gross motor skills and change during normal neuro-
development [13].
Regarding pediatric patients under 4 years of age, at the
present time, big efforts are being performed by patients’
associations and clinicians to develop an ataxia rating
score.
In the present study, differences in ICARS scores be-
tween PMM2-CDG patients and controls were important
and statistically significant. There was no age effect in
patient scores when a “corrected-by-age” ICARS was in-
cluded in the analysis. This fact is probably due to the
limited impact of age compared to the effect of the clinical
phenotype.
When applying ICARS, inter-observer variability varied
between “almost perfect” and “substantial”. Concerning
inter-item reliability for every subscale, the worst results
were obtained regarding oculomotor abnormalities. Thismay be explained by the fact that only three items were
evaluated and by the influence of the collaboration of the
patient, hampering proper scoring and data interpretation.
This methodological issue should prompt reconsideration
of SARA, a scale that does not rely upon evaluation of
oculomotor abnormalities. However, this is a major draw-
back because signs of oculomotor dysfunction were fre-
quently observed in our series of PMM2-CDG patients,
and the oculomotor subscore was significantly higher in
patients compared to controls (Fig. 2a).
Non-cerebellar aspects of the neurological spectrum of
PMM2-CDG patients can act as potential confounders to
ICARS assessment, such as muscle weakness, peripheral
neuropathy, extracerebellar muscle hypotonia and cogni-
tive impairment, increasing the final score. Sival et al.
evaluated sensory ataxia and muscle weakness in children
affected by Friedreich ataxia scored using ICARS [14].
They conclude that only maximal sensory ataxia and pro-
nounced muscle weakness increase the ICARS score,
reaching a maximal plateau. None of our included PMM2-
CDG patients had pronounced muscle weakness or severe
peripheral neuropathy. Moreover, unlike Friedreich ataxia,
spinal cord abnormalities are not included in the PMM2-
CDG phenotype.
Concerning cognitive impairment as a further limita-
tion to ICARS, we facilitated the comprehension of the
different maneuvers by training the patient before the
final evaluation. In addition, we allowed the patients to
imitate movements, as they completed the test together
with their siblings or parents. The evaluators found that
the patients’ comprehension was enough to understand
and perform the maneuvers in thirteen PMM2-CDG
patients. However, one teenager was excluded from the
study due to severe cognitive impairment that precluded
the assessment of ICARS. We found limb coordination
and oculomotor sub-scores the more challenging items
both for patients and controls.
In summary, two main limitations should be considered
in a particular patient when rating a PMM2-CDG patient
Serrano et al. Orphanet Journal of Rare Diseases  (2015) 10:138 Page 8 of 9with ICARS; the level of cooperation/comprehension as
well as sensory abnormalities and/or peripheral neur-
opathy. Considering that PMM2-CDG patients usually
associate cognitive impairment, their neurodevelopmental
quotient is relevant for the interpretation of ICARS.
Finally, future longitudinal studies will be necessary to
demonstrate the validity of this scale when assessing the
progression of cerebellar manifestations in PMM2-CDG.
The NPCRS is a scale based on the Newcastle Pediatric
Mitochondrial Disease Scale recently validated for CDG
patients, reflecting cross-usefulness in these two groups of
diseases with multiple organ system involvement [11]. Al-
though NPCRS is a good tool for the global evaluation of
the patient, it has poor specificity for cerebellar symptoms.
In PMM2-CDG, ataxia, and, to a lesser extent, other
neurological abnormalities, appear to be the main cause of
the patients’ daily limitations. Therefore, the ICARS seems
a more precise option when addressing functional disabil-
ity in PMM2-CDG. In our study there was a good correl-
ation between ICARS and total NPCRS results. However,
the NPCRS did not seem to discriminate between moder-
ate and severe cerebellar phenotypes.
Due to the broad mutation spectrum in the Spanish
population [8], and our limited sample size, our ability
to reach conclusions regarding genotype-phenotype corre-
lations is limited. However, some conclusions can be
drawn by taking into account the reported functional
effects of some mutations [18], and the patient’s pheno-
type described in this work. Among our patients, p.E93A,
p.C241S and p.R162W mutations that retain residual ac-
tivity, combined with null missense mutations with no re-
sidual activity (p.R141H, p.R123Q or p.F157S) or splicing
and nonsense mutations (c.523 + 3A >G and p.R123X)
were observed with milder phenotypes. Therefore, these
mutations p.E93A, p.C241S and p.R162W can be consid-
ered milder mutations. It is noteworthy that the two
homozygous patients present the most severe phenotype.
Regarding the mutation showed by patient 13, the
p.E139K mutant protein retains 25 % of its residual activ-
ity, and the protein can be expressed at a sufficient level
in vivo to confer residual activity compatible with life [19],
being found in milder phenotypes. Concerning the muta-
tion showed by patient 13, p. P113L mutation affects
PMM2 dimerization and is present in this work in three
patients associated with different phenotypes being associ-
ated with a less severe phenotype in heterozygosity [18].
Importantly, patients 12 and 13 presented a segmental
maternal chromosome isodisomy [20] a genetic condition
reported in chromosome 16 [21]; other sequence variants
present in this homozygous region could affect the clinical
features in these two patients.
An important neurological feature in PMM2-CDG is
cerebellar ataxia. No clear correlation between the sever-
ity of ataxia and cerebellar imaging has been reportedpreviously. In our sample, an apparent relationship was
observed between ICARS and the severity of cerebellar
atrophy because higher ICARS scores were associated
with wider inter-folia spaces and lower cerebellar vol-
umes by visual inspection. A more objective, simple and
very easy measure is the midsagittal vermis relative diam-
eter as performed on MRI studies. A negative correlation
between cerebellar measures and ICARS supports a clin-
ical and anatomical correlation; however, this simple
measure can be biased by many factors. 3D segmentation
and measurement of the cerebellum has proven to be
most accurate in assessing cerebellar volume as has been
reported in other genetic diseases [22]. Unfortunately, in
the vast majority of our recruited patients, only non-
volumetric MRI scans were available. Therefore, we have
been forced to use a linear measurement approach similar
to the classic fetal cerebellum measurements [16, 17], in
order not to repeat MRI examinations for ethical reasons
(most of the patients would probably need sedation).
Although this method is not as precise, it is easily repro-
ducible and is able to show gross cerebellum size anomal-
ies in relationship to the posterior fossa size. Furthermore,
in patients with more than one MRI, a progression of
the cerebellum atrophy was found (data not reported).
Whether this neuroimaging progression correlates with a
measurable clinical worsening and whether this progres-
sion is pointing toward a therapeutic window deserves
further studies.
Regarding supratentorial abnormalities, patient 13
showed lateral ventricular enlargement. This patient under-
went cardiac surgery during the newborn period and
suffered a prolonged cardiorespiratory arrest during the
procedure. This hypoxic-ischemic event may explain neu-
roimaging findings aside from the expected cerebellar
atrophy.
The cerebellum, while once considered a brain region
principally involved in motor control and coordination,
is increasingly associated with a range of neuropsycho-
logical and neuropsychiatric presentations. In patients
who suffer from different cerebellar disorders, cerebellar
degeneration and focal cerebellar lesions, impairments
in attention, memory, executive functions and intelligence
quotient demonstrate that the cerebellum likely plays a
significant role in numerous higher cognitive functions
such as language, cognitive and emotional functions [23].
The analysis of all of these traits in our patients was not
within the scope of our present work. However, interest-
ingly, a negative correlation between ICARS and QI was
found. Again, this is a complex issue that deserves further
study.
Conclusions
In conclusion, our study demonstrates the reliability of
ICARS for the assessment of cerebellar involvement in
Serrano et al. Orphanet Journal of Rare Diseases  (2015) 10:138 Page 9 of 9PMM2-CDG patients, showing no significant inter-rater
variability. Our results suggest a correlation between cere-
bellar symptoms and neuroimaging findings that needs to
be further explored.
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